All News
Beyond the Scale: Do GLP-1RAs Offer More Than Weight Loss in PsA?
Over 70% of patients with PsA struggle with excess weight, amplifying synovio-entheseal inflammation and blunting biologic response. The rapid uptake of GLP-1RAs in rheumatology has raised an urgent mechanistic question: are clinical gains in PsA driven purely by weight reduction, or do these agents carry intrinsic anti-inflammatory properties? EULAR 2026 offered six abstracts that together illuminate, without fully resolving, this question.
Read Article
Aurelie Najm AurelieRheumo ( View Tweet)
Jiha Lee JihaRheum ( View Tweet)
Nelly ZIADE π Nellziade ( View Tweet)
Nelly ZIADE π Nellziade ( View Tweet)
π₯ TOGETHER-PsA (OP069) #EULAR2026 #EULARbest Ixekizumab + Tirzepatide vs IXE alone in PsA with obesity/overweight: β Primary endpoint (ACR50 + β₯10% wt loss at W36): 31.7% vs. 0.8% (p<0.001) β ACR50: 33.5% vs. 20.4% β MDA: 26.3% vs. 15.3% (p=0.026) @rheumnow @DrLauraCoates https://t.co/6wh3S6khXw
Nelly ZIADE π Nellziade ( View Tweet)
Nelly ZIADE π Nellziade ( View Tweet)
Nelly ZIADE π Nellziade ( View Tweet)
Links:
Bella Mehta bella_mehta ( View Tweet)
Antoni Chan MD (Prof) synovialjoints ( View Tweet)


